stocktitan.netSEP 141 min read$NBIX

Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale

Neurocrine Biosciences (NBIX) officer David Warren Boyer filed a Rule 144 notice to sell 4,714 shares, valued at approximately $736,421, from vested restricted and performance stock units between January 31, 2026, and September 14, 2026, according to the company.

Original reporting

stocktitan.net

Published Sep 14, 2026, 8:47 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 3:50 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$NBIX

Neutral

high confidence

Mentioned

$NBIX

Relevance

4/10

AlphAI data visualization · based on stocktitan.net

Decision brief

The 30-second read

$NBIXNeutralLow

Why it matters

The disclosed sale represents a small fraction of NBIX's float and is unlikely to affect liquidity or price.

Market read

Routine insider sale with limited trading relevance.

What to watch

Potential future sales if more units vest later; cumulative insider selling could become material.

Relevance 4/10Novelty 3/10Timing: September 14, 2026 (date of filing)

Background

Form 144 filings disclose planned sales of restricted or performance‑based shares by insiders, providing transparency on potential future supply.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NBIXNeutralHigh confidence

Context

Officer David Warren Boyer filed a Form 144 to sell 4,714 NBIX shares valued at $736,421.

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

Sale size is small relative to market cap and typical insider transactions of this magnitude have negligible effect.

Market effects

Sector

None; biotech sector not affected by a single small insider sale.

Regional

None; impact confined to US market and limited to NBIX.

Global

None

Counterpoint

What could challenge this read

If the insider is offloading shares, it could signal concerns about near‑term performance.

Key entities

Company
Neurocrine Biosciences Inc.
US‑listed biotech company (NASDAQ: NBIX).
Insider
David Warren Boyer
Officer of Neurocrine filing the Rule 144 notice.

Read at source ← All news

SEP 28

$NBIXLow

Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes

Neurocrine Biosciences, Inc. announced Eiry W. Roberts, M.D., will return as Chief Medical Officer, effective September 28, 2026. Dr. Sanjay Keswani's tenure as CMO ended on September 25, 2026. Dr. Roberts previously led key drug development programs at Neurocrine.

marketscreener.com2 min

SEP 18

$NBIXMedAI 8/10

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.

insidermonkey.com2 min

SEP 9

$NBIXMedAI 8/10

NBIX: Strong revenue growth and robust product performance set the stage for future pipeline catalysts

Neurocrine Biosciences reported $1B in quarterly revenue, driven by Ingrezza, CRENESSITY, and VYKAT XR. Ingrezza saw double-digit growth, while CRENESSITY exceeded expectations. The company expects major pipeline catalysts in 2027–2028, according to a Wells Fargo conference transcript.

tradingview.com1 min

AUG 26

$NBIXHighAI 8/10

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer’s Cognition

Nxera Pharma's partner, Neurocrine Biosciences, received FDA IND Acceptance for a Phase 2 study of NBI-1117567, an Alzheimer's cognition treatment. Nxera will receive a $10 million milestone payment, recognized as revenue in Q3 FY2026. Nxera retains development rights in Japan.

sina.com.hk2 min

AUG 12

$NBIXMed

Why is Neurocrine Biosciences stock sliding today?

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

investing.com6 min

AUG 8